Ocular Inflammation and Uveitis: Insights into Immunology and Therapeutics

Autores

DOI:

https://doi.org/10.55892/jrg.v8i19.2467

Palavras-chave:

Ocular inflammation, Uveitis, Immunology, Biological therapies

Resumo

Ocular inflammation, particularly uveitis, represents a significant global cause of visual impairment and blindness, affecting individuals across different age groups and geographical regions. This work provides a comprehensive overview of the immunological basis of ocular inflammation, with emphasis on cytokines, chemokines, and cellular infiltration processes that contribute to the pathophysiology of uveitis. The study reviews the epidemiology, classification, and clinical manifestations of uveitis, highlighting the impact of infectious and non-infectious etiologies. Special attention is given to the molecular pathways involved in ocular immunity, as well as to the advances in immunomodulatory and biological therapies, such as monoclonal antibodies and emerging nanomedicine-based strategies. The discussion also addresses the challenges of treatment adherence, adverse effects of conventional therapies, and the need for personalized medicine. Future perspectives point to the integration of gene therapy and artificial intelligence as promising tools to optimize diagnosis, management, and prognosis of ocular inflammatory diseases. These insights contribute to a deeper understanding of ocular immunopathology and pave the way for safer and more effective therapeutic strategies. 

Downloads

Não há dados estatísticos.

Biografia do Autor

Gabriela Cecilio Ventura Bariani Belem, Universidade Federal do Rio de Janeiro, RJ, Brasil

Médica pela Universidade Federal do Rio de Janeiro – UFRJ, 2017; Fellow clínico e cirúrgico em córnea e doenças externas pela Universidade Federal de Goiás - UFG – CEROF, 2022.

George Harrison Ferreira de Carvalho, Universidade de Brasília (UnB).

Doutor em Ciências Médicas pela Universidade de Brasília (UnB) 2018. Mestre em Medicina Tropical pelo Instituto de Patologia Tropical  e  Saúde  Pública  da  Universidade  Federal  de  Goiás  IPTSP/  UFG  (2011).  Especialização  em  Epidemiologia Multidisciplinar  e  Especialização  em  Estética  Clínica  ambas  pela  CGESP  (2023).  Graduações  superiores  (Biologia  e Enfermagem) sendo, licenciatura em Biologia e bacharelado em Enfermagem.

 

Referências

BABU, Kalpana; MAHENDRADAS, Padmamalini. Medical management of uveitis–current trends. Indian journal of ophthalmology, v. 61, n. 6, p. 277-283, 2013.

BALASUBRAMANIAM, Balini et al. Topical anti-inflammatory agents for non-infectious uveitis: current treatment and perspectives. Journal of Inflammation Research, p. 6439-6451, 2022.

BAR, Asaf et al. Medical Management of Uveitis. In: UVEITIS MANAGEMENT: A Clinical Handbook. 2023. p. 205-227.

DE CARVALHO, G. H. F.; DE MEDEIROS, G. G.; MAGALHÃES, R. L. B. Subnotificação de doença de Chagas no Estado do Amapá no período da pandemia de COVID-19. Caderno Pedagógico, v. 21, n. 9, p. e7609-e7609, 2024.

DENNISTON, Alastair K.; DICK, Andrew D. Systemic therapies for inflammatory eye disease: past, present and future. BMC ophthalmology, v. 13, n. 1, p. 18, 2013.

GHORABA, Hashem H. et al. Ocular gene therapy: a literature review with special focus on immune and inflammatory responses. Clinical Ophthalmology, p. 1753-1771, 2022.

GONZALEZ CALDITO, N. Role of tumor necrosis factor-alpha in the central nervous system: a focus on autoimmune disorders, Frontiers in Immunology, 2023.

HENRIQUES, Cristina et al. Monoclonal antibodies for the treatment of ocular diseases. Journal of Clinical Medicine, v. 13, n. 19, p. 5815, 2024.

HUANG, X. F.; A. BROWN, M. Progress in the genetics of uveitis, 2022.

HYSA, Elvis et al. Immunopathophysiology and clinical impact of uveitis in inflammatory rheumatic diseases: An update. European journal of clinical investigation, v. 51, n. 8, p. e13572, 2021.

J BARRY, R.; DONG NGUYEN, Q.; W LEE, R.; I MURRAY, P. et al. Pharmacotherapy for uveitis: current management and emerging therapy, 2014.

J. EPPS, S.; BOLDISON, J.; L. STIMPSON, M.; K. KHERA, T. et al. Re-programming immunosurveillance in persistent non-infectious ocular inflammation, 2018.

JANG, Dan-in et al. The role of tumor necrosis factor alpha (TNF-α) in autoimmune disease and current TNF-α inhibitors in therapeutics. International journal of molecular sciences, v. 22, n. 5, p. 2719, 2021.

JOLTIKOV, K. A.; LOBO-CHAN, A. M. Epidemiology and risk factors in non-infectious uveitis: a systematic review, Frontiers in medicine, 2021.

KAI CHAN, Y.; D. DICK, A.; MARY HALL, S.; LANGMANN, T. et al. Inflammation in Viral Vector-Mediated Ocular Gene Therapy: A Review and Report From a Workshop Hosted by the Foundation Fighting Blindness, 9/2020, 2021.

LI, Jeany Q. et al. Prevalence and incidence of registered severe visual impairment and blindness due to uveitis in Germany. Ocular Immunology and Inflammation, v. 32, n. 5, p. 735-739, 2024.

LOPES TRONCOSO, L.; LUIZA BIANCARDI, A.; VIEIRA DE MORAES JR, H.; ZALTMAN, C. Ophthalmic manifestations in patients with inflammatory bowel disease: A review, 2017.

M. HORNBEAK, D.; E. THORNE, J. Immunosuppressive therapy for eye diseases: Effectiveness, safety, side effects and their prevention, 2015.

M. SHARMA, S.; JACK FU, D.; XUE, K. A Review of the Landscape of Targeted Immunomodulatory Therapies for Non-Infectious Uveitis, 2018.

MASSILAMANY, C.; GANGAPLARA, A.; REDDY, J. Environmental microbes and uveitis: is microbial exposure always bad? Scandinavian Journal of Immunology, v. 81, n. 6, p. 469-475, 2015.

MÉRIDA, S.; PALACIOS, E.; NAVEA, A.; BOSCH-MORELL, F. Macrophages and Uveitis in Experimental Animal Models, 2015.

MOUSTARDAS, P.; ABERDAM, D.; LAGALI, N. MAPK pathways in ocular pathophysiology: potential therapeutic drugs and challenges, Cells, 2023.

MRUGACZ, M.; BRYL, A.; FALKOWSKI, M.; ZORENA, K. Integrins: an important link between angiogenesis, inflammation and eye diseases, Cells, 2021.

OZGA, A. J.; CHOW, M. T.; LUSTER, A. D. Chemokines and the immune response to cancer, Immunity, 2021.

PAPIEŻ, M. A.; KRZYŚCIAK, W. Biological therapies in the treatment of cancer—update and new directions, International journal of molecular sciences, 2021.

PAPOTTO, Pedro Henrique et al. Novel CD28 antagonist mPEG PV1-Fab’mitigates experimental autoimmune uveitis by suppressing CD4+ T lymphocyte activation and IFN-γ production. PLoS One, v. 12, n. 3, p. e0171822, 2017.

PRADO, Karollyne Francisco et al. Uveitis: Ocular Manifestations of Rheumatic Diseases and Multidisciplinary Approaches. Brazilian Journal of Implantology and Health Sciences, v. 6, n. 5, p. 956-968, 2024.

PUROHIT, Manish et al. Janus kinase/signal transducers and activator of transcription (JAK/STAT) and its role in Lung inflammatory disease. Chemico-Biological Interactions, v. 371, p. 110334, 2023.

REEKIE, Ian R. et al. The cellular composition of the uveal immune environment. Frontiers in Medicine, v. 8, p. 721953, 2021.

SÁNCHEZ-ROBLES, Eva M. et al. Monoclonal antibodies for chronic pain treatment: present and future. International Journal of Molecular Sciences, v. 22, n. 19, p. 10325, 2021.

SHARMA, Y.; ARORA, M.; BALA, K. The potential of immunomodulators in shaping the future of healthcare, Discover Medicine, 2024.

SU, Jiajia et al. Fine-tuning of liposome integrity for differentiated transcytosis and enhanced antitumor efficacy. Journal of Controlled Release, v. 372, p. 69-84, 2024.

TEABAGY, Sean et al. Ocular immunosuppressive microenvironment and novel drug delivery for control of uveitis. Advanced drug delivery reviews, v. 198, p. 114869, 2023.

TEO, Andrea York Tiang et al. Intermediate uveitis: a review. Ocular Immunology and Inflammation, v. 31, n. 5, p. 1041-1060, 2023.

THNG, Zheng Xian et al. Recent advances in uveitis therapy: focus on selected phase 2 and 3 clinical trials. Expert Opinion on Emerging Drugs, v. 28, n. 4, p. 297-309, 2023.

TSIROUKI, Theodora et al. A focus on the epidemiology of uveitis. Ocular immunology and inflammation, v. 26, n. 1, p. 2-16, 2018.

VAN LAAR, JAN AM et al. Diagnosis and Treatment of Uveitis; not Restricted to the Ophthalmologist. Journal of Clinical and Translational Research, V. 1, N. 2, P. 94, 2015., 2015.

VENKATAPATHAPPA, P.; SULTANA, A.; K S, V.; MANSOUR, R. et al. Ocular Pathology and Genetics: Transformative Role of Artificial Intelligence (AI) in Anterior Segment Diseases, 2024.

WELGE-LUSSEN, U.; WEISE, S.; L. YU, A. Assessing the adherence behavior of glaucoma patients to topical eye drops, 2015.

WILDNER, Gerhild et al. Pathogenesis of bacterial Uveitis. Ocular Immunology and Inflammation, v. 31, n. 7, p. 1396-1404, 2023.

WU, Xue et al. Pathogenesis and current therapies for non-infectious uveitis. Clinical and Experimental Medicine, v. 23, n. 4, p. 1089-1106, 2023.

XU, H.; RAO, N. A. Grand challenges in ocular inflammatory diseases, Frontiers in Ophthalmology, 2022.

Y. SERPEN, J.; T. ARMENTI, S.; PRASOV, L. Immunogenetics of the Ocular Anterior Segment: Lessons from Inherited Disorders, 2021.

ZAKI, A. M.; SUHLER, E. B. Biologics in non-infectious uveitis past, present and future, Annals of Eye Science, 2021.

ZHANG, Miao et al. The role of oxidative stress in the pathogenesis of ocular diseases: An overview. Molecular Biology Reports, v. 51, n. 1, p. 454, 2024.

Downloads

Publicado

2025-10-02

Como Citar

BELEM, G. C. V. B.; CARVALHO, G. H. F. de. Ocular Inflammation and Uveitis: Insights into Immunology and Therapeutics. Revista JRG de Estudos Acadêmicos , Brasil, São Paulo, v. 8, n. 19, p. e082467, 2025. DOI: 10.55892/jrg.v8i19.2467. Disponível em: http://revistajrg.com/index.php/jrg/article/view/2467. Acesso em: 2 out. 2025.

Edição

v. 8 n. 19 (2025): Revista JRG de Estudos Acadêmicos

Seção

Artigos

ARK

https://n2t.net/ark:/57118/JRG.v8i19.2467

Licença

Creative Commons License
Este trabalho está licenciado sob uma licença Creative Commons Attribution 4.0 International License.